The FDA approved the regimens in June 2020 for treating HER2-positive both early and metastatic breast cancers, while trastuzumab with tucatinib has been granted accelerated approval for colorectal cancer recently [76,77]. This evidence concerns the gene ERBB2 and breast cancer.